No Cover Image

Journal article 652 views 79 downloads

SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study

Niklas Frahm Orcid Logo, Firas Fneish, David Ellenberger, Judith Haas, Micha Loebermann, Tina Parciak, Melanie Peters, Dieter Pöhlau, Jeff Rodgers, Anna-Lena Röper, Sarah Schilling, Alexander Stahmann, Herbert Temmes, Uwe K. Zettl, Rod Middleton Orcid Logo

The Lancet Regional Health - Europe, Volume: 22, Start page: 100502

Swansea University Authors: Jeff Rodgers, Rod Middleton Orcid Logo

  • 61480_VoR.pdf

    PDF | Version of Record

    Copyright: 2022 MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH). This is an open access article under the CC BY-NC-ND license

    Download (2.19MB)

Check full text

DOI (Published version): 10.1016/j.lanepe.2022.100502

Abstract

BackgroundVaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deteriorati...

Full description

Published in: The Lancet Regional Health - Europe
ISSN: 2666-7762
Published: Elsevier BV 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa61480
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-10-20T15:02:50Z
last_indexed 2023-01-13T19:22:15Z
id cronfa61480
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-10-20T16:05:40.1356980</datestamp><bib-version>v2</bib-version><id>61480</id><entry>2022-10-07</entry><title>SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study</title><swanseaauthors><author><sid>3ee27bde2acae56844ecdcbb563218ac</sid><firstname>Jeff</firstname><surname>Rodgers</surname><name>Jeff Rodgers</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>005518f819ef1a2a13fdf438529bdfcd</sid><ORCID>0000-0002-2130-4420</ORCID><firstname>Rod</firstname><surname>Middleton</surname><name>Rod Middleton</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-10-07</date><deptcode>HDAT</deptcode><abstract>BackgroundVaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deterioration following SARS-CoV-2 vaccinations in German and United Kingdom (UK) PwMS, especially regarding gender-specific differences.MethodsThe German Multiple Sclerosis Society and the UK MS Registry acquired health data via an online system following the first (X1) and second SARS-CoV-2 vaccination (X2), respectively: sociodemographic and clinical data, vaccines used, VRs, MS deterioration (worsened or new MS symptoms, Germany only) and relapses (Germany only). The frequencies of VRs and MS deterioration were analysed stratified by gender.FindingsFollowing X1 (X2), 2346 (1835) German PwMS and 3796 (683) UK PwMS participated in the study. The most frequent vaccination scheme was two-dose tozinameran for Germany (77&#xB7;1%, 1424/1847) and two-dose AZD1222 for the UK (61&#xB7;3%, 419/683). The most common VRs were fatigue, headache and pain (at the injection site) and occurred more often in women compared with men. German PwMS reported VRs more frequently after X2 vs. X1 (65&#xB7;4% [1201/1835] vs. 61&#xB7;2% [1435/2346]), while for UK patients it was the opposite (X1 vs. X2: 48&#xB7;7% [1849/3796] vs. 30&#xB7;0% [205/683]). MS deterioration occurred in 19&#xB7;0% (445/2346) of the German PwMS without resulting in gender-specific differences. Fatigue and gait impairment were the most frequent deteriorated MS symptoms.InterpretationFemale PwMS reported experiencing VRs more often than men. Longitudinal data are needed to enable valid statements regarding long-term MS deterioration and long-lasting VRs.</abstract><type>Journal Article</type><journal>The Lancet Regional Health - Europe</journal><volume>22</volume><journalNumber/><paginationStart>100502</paginationStart><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2666-7762</issnPrint><issnElectronic/><keywords>SARS-CoV-2; COVID-19; Vaccination; Vaccination reaction; Multiple sclerosis; Gender; Adverse events</keywords><publishedDay>1</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-11-01</publishedDate><doi>10.1016/j.lanepe.2022.100502</doi><url/><notes/><college>COLLEGE NANME</college><department>Health Data Science</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>HDAT</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>German Multiple Sclerosis Society (DMSG Bundesverband e.V.), Biogen, Bristol Myers Squibb, Merck Serono, Mylan, Novartis, Roche and Sanofi.</funders><projectreference/><lastEdited>2022-10-20T16:05:40.1356980</lastEdited><Created>2022-10-07T11:58:57.1243395</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Niklas</firstname><surname>Frahm</surname><orcid>0000-0002-4655-774x</orcid><order>1</order></author><author><firstname>Firas</firstname><surname>Fneish</surname><order>2</order></author><author><firstname>David</firstname><surname>Ellenberger</surname><order>3</order></author><author><firstname>Judith</firstname><surname>Haas</surname><order>4</order></author><author><firstname>Micha</firstname><surname>Loebermann</surname><order>5</order></author><author><firstname>Tina</firstname><surname>Parciak</surname><order>6</order></author><author><firstname>Melanie</firstname><surname>Peters</surname><order>7</order></author><author><firstname>Dieter</firstname><surname>P&#xF6;hlau</surname><order>8</order></author><author><firstname>Jeff</firstname><surname>Rodgers</surname><order>9</order></author><author><firstname>Anna-Lena</firstname><surname>R&#xF6;per</surname><order>10</order></author><author><firstname>Sarah</firstname><surname>Schilling</surname><order>11</order></author><author><firstname>Alexander</firstname><surname>Stahmann</surname><order>12</order></author><author><firstname>Herbert</firstname><surname>Temmes</surname><order>13</order></author><author><firstname>Uwe K.</firstname><surname>Zettl</surname><order>14</order></author><author><firstname>Rod</firstname><surname>Middleton</surname><orcid>0000-0002-2130-4420</orcid><order>15</order></author></authors><documents><document><filename>61480__25537__20b8a19244f949519d68fadcb6099a74.pdf</filename><originalFilename>61480_VoR.pdf</originalFilename><uploaded>2022-10-20T16:04:10.0287304</uploaded><type>Output</type><contentLength>2295701</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright: 2022 MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH). This is an open access article under the CC BY-NC-ND license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-10-20T16:05:40.1356980 v2 61480 2022-10-07 SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study 3ee27bde2acae56844ecdcbb563218ac Jeff Rodgers Jeff Rodgers true false 005518f819ef1a2a13fdf438529bdfcd 0000-0002-2130-4420 Rod Middleton Rod Middleton true false 2022-10-07 HDAT BackgroundVaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deterioration following SARS-CoV-2 vaccinations in German and United Kingdom (UK) PwMS, especially regarding gender-specific differences.MethodsThe German Multiple Sclerosis Society and the UK MS Registry acquired health data via an online system following the first (X1) and second SARS-CoV-2 vaccination (X2), respectively: sociodemographic and clinical data, vaccines used, VRs, MS deterioration (worsened or new MS symptoms, Germany only) and relapses (Germany only). The frequencies of VRs and MS deterioration were analysed stratified by gender.FindingsFollowing X1 (X2), 2346 (1835) German PwMS and 3796 (683) UK PwMS participated in the study. The most frequent vaccination scheme was two-dose tozinameran for Germany (77·1%, 1424/1847) and two-dose AZD1222 for the UK (61·3%, 419/683). The most common VRs were fatigue, headache and pain (at the injection site) and occurred more often in women compared with men. German PwMS reported VRs more frequently after X2 vs. X1 (65·4% [1201/1835] vs. 61·2% [1435/2346]), while for UK patients it was the opposite (X1 vs. X2: 48·7% [1849/3796] vs. 30·0% [205/683]). MS deterioration occurred in 19·0% (445/2346) of the German PwMS without resulting in gender-specific differences. Fatigue and gait impairment were the most frequent deteriorated MS symptoms.InterpretationFemale PwMS reported experiencing VRs more often than men. Longitudinal data are needed to enable valid statements regarding long-term MS deterioration and long-lasting VRs. Journal Article The Lancet Regional Health - Europe 22 100502 Elsevier BV 2666-7762 SARS-CoV-2; COVID-19; Vaccination; Vaccination reaction; Multiple sclerosis; Gender; Adverse events 1 11 2022 2022-11-01 10.1016/j.lanepe.2022.100502 COLLEGE NANME Health Data Science COLLEGE CODE HDAT Swansea University German Multiple Sclerosis Society (DMSG Bundesverband e.V.), Biogen, Bristol Myers Squibb, Merck Serono, Mylan, Novartis, Roche and Sanofi. 2022-10-20T16:05:40.1356980 2022-10-07T11:58:57.1243395 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Niklas Frahm 0000-0002-4655-774x 1 Firas Fneish 2 David Ellenberger 3 Judith Haas 4 Micha Loebermann 5 Tina Parciak 6 Melanie Peters 7 Dieter Pöhlau 8 Jeff Rodgers 9 Anna-Lena Röper 10 Sarah Schilling 11 Alexander Stahmann 12 Herbert Temmes 13 Uwe K. Zettl 14 Rod Middleton 0000-0002-2130-4420 15 61480__25537__20b8a19244f949519d68fadcb6099a74.pdf 61480_VoR.pdf 2022-10-20T16:04:10.0287304 Output 2295701 application/pdf Version of Record true Copyright: 2022 MS Forschungs- und Projektentwicklungs-gGmbH (MS Research and Project Development gGmbH). This is an open access article under the CC BY-NC-ND license true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
spellingShingle SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
Jeff Rodgers
Rod Middleton
title_short SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
title_full SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
title_fullStr SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
title_full_unstemmed SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
title_sort SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
author_id_str_mv 3ee27bde2acae56844ecdcbb563218ac
005518f819ef1a2a13fdf438529bdfcd
author_id_fullname_str_mv 3ee27bde2acae56844ecdcbb563218ac_***_Jeff Rodgers
005518f819ef1a2a13fdf438529bdfcd_***_Rod Middleton
author Jeff Rodgers
Rod Middleton
author2 Niklas Frahm
Firas Fneish
David Ellenberger
Judith Haas
Micha Loebermann
Tina Parciak
Melanie Peters
Dieter Pöhlau
Jeff Rodgers
Anna-Lena Röper
Sarah Schilling
Alexander Stahmann
Herbert Temmes
Uwe K. Zettl
Rod Middleton
format Journal article
container_title The Lancet Regional Health - Europe
container_volume 22
container_start_page 100502
publishDate 2022
institution Swansea University
issn 2666-7762
doi_str_mv 10.1016/j.lanepe.2022.100502
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description BackgroundVaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deterioration following SARS-CoV-2 vaccinations in German and United Kingdom (UK) PwMS, especially regarding gender-specific differences.MethodsThe German Multiple Sclerosis Society and the UK MS Registry acquired health data via an online system following the first (X1) and second SARS-CoV-2 vaccination (X2), respectively: sociodemographic and clinical data, vaccines used, VRs, MS deterioration (worsened or new MS symptoms, Germany only) and relapses (Germany only). The frequencies of VRs and MS deterioration were analysed stratified by gender.FindingsFollowing X1 (X2), 2346 (1835) German PwMS and 3796 (683) UK PwMS participated in the study. The most frequent vaccination scheme was two-dose tozinameran for Germany (77·1%, 1424/1847) and two-dose AZD1222 for the UK (61·3%, 419/683). The most common VRs were fatigue, headache and pain (at the injection site) and occurred more often in women compared with men. German PwMS reported VRs more frequently after X2 vs. X1 (65·4% [1201/1835] vs. 61·2% [1435/2346]), while for UK patients it was the opposite (X1 vs. X2: 48·7% [1849/3796] vs. 30·0% [205/683]). MS deterioration occurred in 19·0% (445/2346) of the German PwMS without resulting in gender-specific differences. Fatigue and gait impairment were the most frequent deteriorated MS symptoms.InterpretationFemale PwMS reported experiencing VRs more often than men. Longitudinal data are needed to enable valid statements regarding long-term MS deterioration and long-lasting VRs.
published_date 2022-11-01T04:20:19Z
_version_ 1763754345186197504
score 11.03559

Similar Items